Date: 2016-12-07
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Neurimmune (Switzerland) TVM Capital Life Science (Germany) AL-S Pharma (Switzerland)
Therapeutic area: Rare diseases - Genetic diseases - Neurodegenerative diseases
Type agreement: establishment of a new company in the EU
Action mechanism:
Disease:
Details: * On December 7, 2016, Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, announced their investment in AL-S Pharma AG, a company based in Schlieren/Zurich, Switzerland. AL-S Pharma will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that was generated and pre-clinically validated by Neurimmune’s Reverse Translational Medicine™ platform. TVM Capital Life Science and AL-S Pharma have the option to engage with Chorus, an autonomous unit of Eli Lilly, to execute an efficient and cost-effective clinical plan. AL-S Pharma will also leverage its extensive product development expertise to potentially bring AP-101 to human proof-of-concept and aims to initiate the first human dose study in ALS patients in 2018 in collaboration with an international network of ALS clinics.
Financial terms:
Latest news:
